Sintilimab in Combination With Chemoradiotherapy in High-risk Locoregionally-advanced Nasopharyngeal Carcinoma

NCT05707819 · clinicaltrials.gov ↗

RECRUITING

Status

43

Enrollment

OTHER

Sponsor class

Conditions

Nasopharyngeal Carcinoma
Sintilimab

Interventions

DRUG: Sintilimab (PD-1 Antibody)

Sponsor

Cancer Hospital of Guangxi Medical University